FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment

Amir Iravani; Medhat Osman; Alison M. Weppler; Roslyn Wallace; Anna Galligan; Arian Lasocki; Morgan Hunter; Tim Akhurst; Michael S. Hofman; Peter K. H. Lau; Damien Kee; George Au‐Yeung; Shahneen Sandhu; Rodney J. Hicks

doi:10.1007/s00259-020-04815-w

Back

FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment

Article 2020 en

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2023

FDG PET/CT Prognostic Markers in Patients with Advanced Melanoma Treated with Ipilimumab and Nivolumab

Amir Iravani, Roslyn Wallace, Serigne Lo, Anna Galligan, Alison M. Weppler, Rodney J. Hicks, Shahneen Sandhu

Article2020

FDG PET in the evaluation of immune-related hypophysitis and thyroiditis following combination ipilimumab and nivolumab in advanced melanoma

Amir Iravani, Anna Galligan, Arian Lasocki, Roslyn Wallace, Alison M. Weppler, George Au Yeung, Tim Akhurst, Nirupa Sachithanandan, Cherie Chiang, Shahneen Sandhu, Rodney J. Hicks

Article2020

FDG-PET metabolic tumor volume in advanced melanoma treated with ipilimumab and nivolumab (ipi/nivo).

Amir Iravani, Roslyn Wallace, Serigne Lo, Anna Galligan, Alison M. Weppler, George Au‐Yeung, Damien Kee, Peter K. H. Lau, Benjamin Brady, Belinda Lee, Grant A. McArthur, Shahneen Sandhu, Rodney J. Hicks

Editorial Material2024

Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Masatoshi Kudo

Letter2017

Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma

Matteo S. Carlino, Shahneen Sandhu